Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation. (2022). Voprosy Onkologii, 67(2), 246-253. https://doi.org/10.37469/0507-3758-2021-67-2-246-253